JP2007513059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513059A5 JP2007513059A5 JP2006529497A JP2006529497A JP2007513059A5 JP 2007513059 A5 JP2007513059 A5 JP 2007513059A5 JP 2006529497 A JP2006529497 A JP 2006529497A JP 2006529497 A JP2006529497 A JP 2006529497A JP 2007513059 A5 JP2007513059 A5 JP 2007513059A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- gastrin
- pharmaceutical composition
- composition according
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 22
- 108010052343 Gastrins Proteins 0.000 claims 16
- 102100021022 Gastrin Human genes 0.000 claims 15
- -1 gastrin compound Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000004877 Insulin Human genes 0.000 claims 11
- 108090001061 Insulin Proteins 0.000 claims 11
- 229940125396 insulin Drugs 0.000 claims 11
- 230000009286 beneficial effect Effects 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical class C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002459 sustained effect Effects 0.000 claims 4
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 102000052874 Gastrin receptors Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229940122985 Peptide agonist Drugs 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- OKGNKPYIPKMGLR-ZPCKCTIPSA-N gastrins Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 OKGNKPYIPKMGLR-ZPCKCTIPSA-N 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940127264 non-peptide agonist Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/016660 WO2003100024A2 (en) | 2002-05-24 | 2003-05-27 | Treatment for diabetes |
| PCT/CA2004/000769 WO2004105780A2 (en) | 2003-05-27 | 2004-05-27 | Compositions comprising gastrin compounds and their use in diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007513059A JP2007513059A (ja) | 2007-05-24 |
| JP2007513059A5 true JP2007513059A5 (enExample) | 2007-07-12 |
Family
ID=33488788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529497A Pending JP2007513059A (ja) | 2003-05-27 | 2004-05-27 | ガストリン化合物を含む組成物および糖尿病におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1648495A2 (enExample) |
| JP (1) | JP2007513059A (enExample) |
| CN (1) | CN1829528A (enExample) |
| AU (1) | AU2004243541A1 (enExample) |
| BR (1) | BRPI0410710A (enExample) |
| CA (1) | CA2527186A1 (enExample) |
| MX (1) | MXPA05012605A (enExample) |
| NO (1) | NO20055582L (enExample) |
| PL (1) | PL379145A1 (enExample) |
| RU (1) | RU2005140518A (enExample) |
| WO (1) | WO2004105780A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1351742B1 (en) | 2001-01-12 | 2008-10-15 | Waratah Pharmaceuticals Inc. | Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| EP1837031B1 (en) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| ES2334268T3 (es) | 2002-06-07 | 2010-03-08 | Waratah Pharmaceuticals, Inc. | Procedimientos y composiciones para el tratamiento de la diabetes. |
| AU2005207870B2 (en) * | 2004-01-30 | 2010-08-19 | Waratah Pharmaceuticals, Inc. | The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels |
| US20100256061A1 (en) * | 2007-03-02 | 2010-10-07 | Antonio Cruz | Gastrin compound for diabetes treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| CA2182034C (en) * | 1994-01-24 | 2009-04-21 | Ronald V. Nardi | Treatment for juvenile diabetes |
| EP1351742B1 (en) * | 2001-01-12 | 2008-10-15 | Waratah Pharmaceuticals Inc. | Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| PL376473A1 (en) * | 2002-10-22 | 2005-12-27 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
-
2004
- 2004-05-27 JP JP2006529497A patent/JP2007513059A/ja active Pending
- 2004-05-27 MX MXPA05012605A patent/MXPA05012605A/es not_active Application Discontinuation
- 2004-05-27 CA CA002527186A patent/CA2527186A1/en not_active Abandoned
- 2004-05-27 RU RU2005140518/15A patent/RU2005140518A/ru not_active Application Discontinuation
- 2004-05-27 BR BRPI0410710-1A patent/BRPI0410710A/pt not_active IP Right Cessation
- 2004-05-27 PL PL379145A patent/PL379145A1/pl not_active Application Discontinuation
- 2004-05-27 EP EP04737749A patent/EP1648495A2/en not_active Withdrawn
- 2004-05-27 WO PCT/CA2004/000769 patent/WO2004105780A2/en not_active Ceased
- 2004-05-27 CN CNA200480022042XA patent/CN1829528A/zh active Pending
- 2004-05-27 AU AU2004243541A patent/AU2004243541A1/en not_active Withdrawn
-
2005
- 2005-11-25 NO NO20055582A patent/NO20055582L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10335462B2 (en) | Use of long-acting GLP-1 peptides | |
| US20250276072A1 (en) | Elp fusion proteins for controlled and sustained release | |
| EP2324853B1 (en) | Lixisenatide as add-on to metformin in the treatment of diabetes type 2 | |
| EP2329848B2 (en) | Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes | |
| JP2006506386A5 (enExample) | ||
| CN103167878A (zh) | 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病 | |
| US20240366533A1 (en) | Sublingual Epinephrine Tablets | |
| US20250319163A1 (en) | Treatment of type 2 diabetes mellitus | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| Tilinca et al. | THE NEWEST THERAPEUTICALLY APPROACH OF" DIABESITY" USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION. | |
| JP2007513059A5 (enExample) | ||
| RU2005140518A (ru) | Композиции и способы, включающие соединения гастрина | |
| Chakraborti | Exenatide: a new promising antidiabetic agent | |
| Pitocco et al. | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents | |
| Kang | Current therapeutic agents and anesthetic considerations for diabetes mellitus | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| Chaurasia | A 100 Years Journey of Insulin | |
| Fredenrich et al. | Dipeptidyl peptidase inhibitors: A new step towards normoglycemia | |
| TW202529797A (zh) | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 | |
| AU2009238271B2 (en) | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin | |
| Ahammad et al. | Incretin-Based Antidiabetic Agents: A New Option for Type-2 Diabetes Mellitus | |
| WO2021142736A1 (en) | Dosing regimen of glp-1 | |
| Plengvidhya | Novel Therapeutic Approach of Type 2 Diabetes Mellitus | |
| Chowdhury | Clinical Pharmacology of DPP-4 Inhibitors | |
| JP2015098464A (ja) | Ｄｐｐ−４阻害剤の増強剤 |